[go: up one dir, main page]

NO304946B1 - Xantinderivat samt dets anvendelse - Google Patents

Xantinderivat samt dets anvendelse

Info

Publication number
NO304946B1
NO304946B1 NO933452A NO933452A NO304946B1 NO 304946 B1 NO304946 B1 NO 304946B1 NO 933452 A NO933452 A NO 933452A NO 933452 A NO933452 A NO 933452A NO 304946 B1 NO304946 B1 NO 304946B1
Authority
NO
Norway
Prior art keywords
straight
alkoxy
branched chain
naphthyl
halogen
Prior art date
Application number
NO933452A
Other languages
English (en)
Norwegian (no)
Other versions
NO933452D0 (no
NO933452L (no
Inventor
Fumio Suzuki
Junichi Shimada
Nobuaki Koyke
Joji Nakamura
Shizuo Shiozaki
Shunji Ichikawa
Hiromi Nonaka
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of NO933452D0 publication Critical patent/NO933452D0/no
Publication of NO933452L publication Critical patent/NO933452L/no
Publication of NO304946B1 publication Critical patent/NO304946B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Radar Systems Or Details Thereof (AREA)
NO933452A 1992-09-28 1993-09-27 Xantinderivat samt dets anvendelse NO304946B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP25783492 1992-09-28

Publications (3)

Publication Number Publication Date
NO933452D0 NO933452D0 (no) 1993-09-27
NO933452L NO933452L (no) 1994-03-29
NO304946B1 true NO304946B1 (no) 1999-03-08

Family

ID=17311787

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933452A NO304946B1 (no) 1992-09-28 1993-09-27 Xantinderivat samt dets anvendelse

Country Status (10)

Country Link
EP (1) EP0590919B1 (fr)
JP (1) JP2613355B2 (fr)
AT (1) ATE188216T1 (fr)
CA (1) CA2107014C (fr)
DE (1) DE69327438T2 (fr)
DK (1) DK0590919T3 (fr)
ES (1) ES2141137T3 (fr)
GR (1) GR3032972T3 (fr)
NO (1) NO304946B1 (fr)
PT (1) PT590919E (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
AU1823895A (en) * 1994-02-23 1995-09-11 Kyowa Hakko Kogyo Co. Ltd. Xanthine derivative
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
EP0814809B1 (fr) 1994-12-13 2003-08-13 Euroceltique S.A. Aryle thioxanthines
CA2206804C (fr) 1994-12-13 2002-03-19 Euro-Celtique, S.A. Thioxanthines trisubstituees
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6727259B2 (en) 1997-09-05 2004-04-27 Kyowa Hakko Kogyo Co., Ltd. Remedial agent for neural degeneration
WO1999030715A1 (fr) * 1997-12-15 1999-06-24 Kyowa Hakko Kogyo Co., Ltd. Agents prophylactiques contre les troubles du sommeil et remedes aux troubles du sommeil
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
AR023966A1 (es) * 1999-05-12 2002-09-04 Fujisawa Pharmaceutical Co Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
EP1234576B1 (fr) * 1999-10-29 2006-03-08 Kyowa Hakko Kogyo Co., Ltd. Remedes contre les troubles de l'alimentation
ATE430749T1 (de) * 2001-02-24 2009-05-15 Boehringer Ingelheim Pharma Xanthinderivate verwendung als arzneimittel sowie deren verfahren zur deren herstellung
TWI330183B (fr) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
CN100395245C (zh) * 2003-05-09 2008-06-18 协和发酵工业株式会社 微晶
TW200507882A (en) * 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
TWI346114B (en) * 2003-09-29 2011-08-01 Method for stabilization of diarylvinylene compounds
ES2532479T3 (es) 2004-01-28 2015-03-27 Kyowa Hakko Kirin Co., Ltd. Agentes para el tratamiento de la migraña
JP5188066B2 (ja) * 2004-12-03 2013-04-24 協和発酵キリン株式会社 薬物依存症の予防および／または治療剤
KR20090094465A (ko) * 2006-12-22 2009-09-07 슈바르츠 파르마 악티엔게젤샤프트 선택적 ａ2ａ 수용체 안타고니스토로서의 8-알키닐잔틴 유도체
US8871751B2 (en) 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
WO2012070601A1 (fr) * 2010-11-24 2012-05-31 ヤマサ醤油株式会社 Nouvelle 2-alkynyl-n9-propargyladénine, et utilisation médicinale de celle-ci
RU2477726C1 (ru) * 2011-10-18 2013-03-20 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные феноксиуксусные кислоты, их эфиры и амиды, включающие 2,6-диоксо-2,3,6,7-тетрагидро-1н-пурин-8-иловый фрагмент, - антагонисты аденозинового a2a рецептора и их применение
RU2480469C1 (ru) * 2012-02-03 2013-04-27 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные 1,3-диэтил-8-винил-7-метил-3,7-дигидро-пурин-2,6-дионы-антагонисты аденозинового a2a рецептора и их применение
CN104744464B (zh) * 2013-11-15 2016-09-21 南京华威医药科技开发有限公司 伊曲茶碱晶型
CN105884776A (zh) * 2014-11-05 2016-08-24 南京瑞天医药科技有限公司 一种伊曲茶碱的新晶型及其制备方法
WO2016148260A1 (fr) * 2015-03-17 2016-09-22 協和発酵キリン株式会社 Composition médicinale
EP3272349A4 (fr) * 2015-03-19 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Agent de traitement et/ou de prévention des maladies à corps de lewy
WO2020125779A1 (fr) * 2018-12-21 2020-06-25 Sunshine Lake Pharma Co., Ltd. Dérivés de styryl xanthine substitués en position 8 et leurs utilisations
CN111333648B (zh) * 2019-04-24 2021-05-11 东莞市东阳光新药研发有限公司 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途
CN110041331B (zh) * 2019-05-17 2020-08-07 广东东阳光药业有限公司 苯乙烯基黄嘌呤衍生物及其用途
WO2021093701A1 (fr) * 2019-11-11 2021-05-20 Sunshine Lake Pharma Co., Ltd. Dérivés de styryl xanthine substitués en position 8 et leurs utilisations
CN111072663B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111018856B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
AU2021235803A1 (en) * 2020-03-10 2022-09-29 Marvel Biotechnology Purine compounds for treating disorders
CN111548351B (zh) * 2020-06-22 2021-03-12 连云港贵科药业有限公司 一种伊曲茶碱的合成方法
CN113248505B (zh) * 2021-06-09 2021-09-21 南京安杰新生物医药有限公司 伊曲茶碱去甲基杂质的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2729642A (en) * 1954-08-13 1956-01-03 Chattanooga Medicine Co Water soluble salts of 8-(para-aminobenzyl) caffeine and method for their preparation
CA929519A (en) * 1969-07-30 1973-07-03 Schweiss Dieter Xanthine compounds and means for obtaining the same
US3624215A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-anxiety agents
US3624216A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-inflammatory agents
US3900474A (en) * 1973-05-14 1975-08-19 Kendall & Co Trifluoroalkyl, fluorobenzyl, pentafluorobenzyl, fluorobenzenesulfonyl, and pentafluorobenzenesulfonyl theophyllines
ES506046A0 (es) * 1981-10-06 1983-02-01 Invest Tecnica Aplicada Procedimiento de obtencion de nuevas xantinas con actividad farmacologica
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
FR2531085A1 (fr) * 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
HU197746B (en) * 1985-09-05 1989-05-29 Sandoz Ag Process for producing xantin derivatives and pharmaceutical compositions containing them
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
WO1992006976A1 (fr) * 1990-10-18 1992-04-30 Kyowa Hakko Kogyo Co., Ltd. Derive de xanthine
CA2093403C (fr) * 1992-04-08 1999-08-10 Fumio Suzuki Agent de traitement de la maladie de parkinson

Also Published As

Publication number Publication date
EP0590919A1 (fr) 1994-04-06
NO933452D0 (no) 1993-09-27
ES2141137T3 (es) 2000-03-16
NO933452L (no) 1994-03-29
JP2613355B2 (ja) 1997-05-28
CA2107014A1 (fr) 1994-03-29
PT590919E (pt) 2000-04-28
ATE188216T1 (de) 2000-01-15
JPH06211856A (ja) 1994-08-02
DE69327438D1 (de) 2000-02-03
DK0590919T3 (da) 2000-04-17
GR3032972T3 (en) 2000-07-31
DE69327438T2 (de) 2000-06-21
EP0590919B1 (fr) 1999-12-29
CA2107014C (fr) 2000-06-13

Similar Documents

Publication Publication Date Title
NO304946B1 (no) Xantinderivat samt dets anvendelse
NO940737L (fr)
NO903438L (no) Fremgangsmaate for fremstilling av tiazolderivater.
DE69021472D1 (de) Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung.
ATE232531T1 (de) Heterobizyklische derivate
ATE52498T1 (de) Amidderivate.
MX9800577A (es) Derivados de 4,5-diaril oxazol.
BR1100636A (pt) Agente terapêutico para o mal de parkinson, e, derivado da xantina
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
EP1034783A4 (fr) Derives d'amide
PT87954A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de dioxopiperidina, com efeito antipsicotico
HUP0202237A2 (hu) Amin, módosított pszeudomicin vegyületek, azokat tartalmazó gyógyászati készítmény és alkalmazásuk

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees